Yahoo Finance Five Star Equities Issues New Research Reports on DCTH, DSCO, NBS and PFE
Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.fivestarequities.com/ and get exclusive access to our numerous stock reports.
Delcath Systems, Inc. (NASDAQ:DCTH - News) shares declined 2.29 percent to close at $0.508 a share Friday. The stock traded between $0.43 and $0.60 on volume of 11.75 million shares traded. The company announced a strategic reorganization under which it has eliminated approximately 33 percent of its global workforce. Shares of Delcath Systems have fallen approximately 58.0 percent year-to-date.
Get more information on Delcath Systems free access to the in-depth equity report at:
www.FiveStarEquities.com/DCTH
Discovery Laboratories, Inc. (NASDAQ:DSCO - News) shares soared 37.06 percent to close at $2.70 a share Friday. The stock traded between $2.65 and $3.05 on volume of 15.23 million shares traded. The company announced the FDA approval of its updated product specifications for SURFAXIN. Shares of Discovery Laboratories have gained approximately 28.0 percent year-to-date.
Get more information on Discovery Laboratories and free access to the in-depth equity report at:
www.FiveStarEquities.com/DSCO
NeoStem Inc. (NASDAQ:NBS - News) shares dropped 9.57 percent to close at $7.09 a share Friday. The stock traded between $7.00 and $7.17 on volume of 2.84 million shares traded. The company announced the pricing of a public offering of 5 million shares of its common stock at a price of $7.00 per share.
Get more information on NeoStem and free access to the in-depth equity report at:
www.FiveStarEquities.com/NBS
Pfizer Inc. (NYSE:PFE - News) shares increased 0.80 percent to close at $29.00 a share Friday. The stock traded between $28.60 and $29.04 on volume of 19.54 million shares traded. The company announced that the FDA approved DUAVEE for the treatment of moderate-to-severe vasomotor symptoms associated with menopause and the prevention of postmenopausal osteoporosis. Shares of Pfizer have gained approximately 15.0 percent year-to-date.
Get more information on Pfizer and free access to the in-depth equity report at:
www.FiveStarEquities.com/PFE
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Contact:
Five Star Equities
info@fivestarequities.com
